A recent study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting productsforsinusitis to allergens such as animals, mold, dust, and pollen. They are called suppressor cells or productsforsinusitis CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients with hay fever by providing the patient’s suppressor cells with the sustained and elevated blood B12 level they need to grow and divide. It appears that by helping the immune system to become what it is genetically capable of becoming, this medicationTM turns at least some allergic people into non-allergic or moderately-allergic people.

Genentech productsforsinusitis and Novartis are developing an anti-IgE monoclonal antibody for asthma and allergic rhinitis. In December 1999 they announced positive study results. This is evidence that reducing IgE results in a reduction of symptoms associated with IgE-mediated allergic disease.13 For people who find they cannot adequately avoid the allergens, the symptoms often can be controlled with medications. Effective medications that can be prescribed by a physician include antihistamines, topical nasal steroids, and productsforsinusitis cromolyn sodium - any of which can be used alone or in combination. Many effective antihistamines and decongestants also are available without a prescription. Click here for allergy medication productsforsinusitis and productsforsinusitis online.

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of productsforsinusitis sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of the treatment. The panel seemed to be in agreement that the statistics indicated productsforsinusitis a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied productsforsinusitis five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6